<- Go Home
Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Market Cap
$6.8M
Volume
593.0K
Cash and Equivalents
$10.3M
EBITDA
-$5.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$12.1M
Profit Margin
33.33%
52 Week High
$3.90
52 Week Low
$1.17
Dividend
N/A
Price / Book Value
0.27
Price / Earnings
-0.55
Price / Tangible Book Value
0.29
Enterprise Value
-$2.5M
Enterprise Value / EBITDA
0.49
Operating Income
-$5.5M
Return on Equity
25.65%
Return on Assets
-11.18
Cash and Short Term Investments
$10.3M
Debt
$929.0K
Equity
$25.7M
Revenue
$36.3M
Unlevered FCF
-$7.8M
Sector
Biotechnology
Category
N/A